- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about INCY
Recent news which mentions INCY
7 Defensive Stocks to Buy for a Bear Market
June 27, 2022
From InvestorPlace
From Motley Fool
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
June 14, 2022
From Benzinga
From Benzinga
From Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
June 14, 2022
From Benzinga
From MarketWatch
From Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2022
May 18, 2022
From Motley Fool
From Motley Fool
From Benzinga
Why CTI Biopharma Stock Is Surging Today
May 13, 2022
From Motley Fool
From Benzinga
WHO head censored in China after criticizing zero-COVID policy, and U.S. cases up 52% from two weeks ago
May 11, 2022
From MarketWatch
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
May 11, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
3 Nasdaq Stocks to Buy Now for Growth
May 01, 2022
From InvestorPlace
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
April 22, 2022
From Benzinga
From Benzinga
Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder
March 28, 2022
Tickers
INCY
From Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
March 28, 2022
From Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
March 24, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.